SCHEMBL3898596

SCHEMBL3898596

NC(=S)Nc1ccc(S(=O)(=O)O)c2ccccc12.[NaH]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
ALOX12 P18054 1/20 0.51
CYP2C19 P33261 1/20 0.51
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
CD40 P25942 1/20 0.44
CD40LG P29965 1/20 0.44
TTR P02766 1/20 0.44
CCR8 P51685 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 1/20 0.39
AURKA O14965 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3897059 0.98 ALDH1A1 (0.53) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3898592 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL27472002 0.80 L3MBTL1 (0.50) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL6120265 0.80 CD40 (0.50) ALDH1A1KDM4EMEN1KMT2ACYP1A2
SCHEMBL4115318 0.79 KMT2A (0.57) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL4353264 0.79 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2CYP3A4
SCHEMBL4252930 0.78 TTR (0.50) ALDH1A1KDM4EMEN1KMT2ACYP1A2
SCHEMBL27469363 0.78 L3MBTL1 (0.52) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL9649084 0.78 CD40 (0.46) ALDH1A1MEN1KMT2ACYP1A2CD40
SCHEMBL1857055 0.78 KMT2A (0.59) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572459-B2 Prevention infections in humans, animals STARPHARMA PTY LTD. (AU) 2009-08-11 US disclosed
EP-1113806-B1 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA PTY LTD (AU) 2007-09-05 EP disclosed
EP-0765357-B9 ANTIVIRAL DENDRIMERS STARPHARMA PTY LTD (AU) 2006-08-16 EP disclosed
EP-0927217-B1 ANGIOGENIC INHIBITORY COMPOUNDS STARPHARMA PTY LTD (AU) 2006-05-03 EP disclosed
EP-0765357-B8 ANTIVIRAL DENDRIMERS STARPHARMA PTY LTD (AU) 2006-03-08 EP disclosed
EP-0765357-B1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RES INST LTD (AU) 2005-12-14 EP disclosed
EP-1113805-A4 INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS STARPHARMA LTD (AU) 2004-05-19 EP disclosed
US-20030129158-A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions STARPHARMA LIMITED 2003-07-10 US disclosed
EP-1113806-A4 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA LTD (AU) 2003-06-25 EP disclosed
EP-0927217-A4 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RES INST LTD (AU) 2003-04-23 EP disclosed
EP-1113805-A1 INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS Starpharma Limited (AU) 2001-07-11 EP disclosed
EP-1113806-A1 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS Starpharma Limited (AU) 2001-07-11 EP disclosed
US-6190650-B1 FOR PROPHYLAXIS AND THERAPY OF VIRAL DISEASES IN HUMANS AND ANIMALS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 2001-02-20 US disclosed
WO-2000015240-A1 ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS STARPHARMA LIMITED (AU) 2000-03-23 WO disclosed
WO-2000015239-A1 INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS STARPHARMA LIMITED (AU) 2000-03-23 WO disclosed
EP-0927217-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1999-07-07 EP disclosed
WO-1998003573-A1 ANGIOGENIC INHIBITORY COMPOUNDS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1998-01-29 WO disclosed
EP-0765357-A4 ANTIVIRAL DENDRIMERS BIOMOLECULAR RES INST LTD (AU) 1997-07-30 EP disclosed
EP-0765357-A1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1997-04-02 EP disclosed
WO-1995034595-A1 ANTIVIRAL DENDRIMERS BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030129158-A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions FUT6, B3GNT2, SIGLEC7 ALDH1A1 2800/4885KDM4E 4773/4885MEN1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.